Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...

Libevitug works by blocking hepatitis B and D viruses from entering liver cells, targeting the PreS1 domain of the viral ...

Huahei Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus (HDV), ...

Understanding what hepatitis C is, how it spreads and how it is treated can replace fear with clarity.

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

Chinese biotech Huahui Health has won conditional approval for Libevitug (libevitug) to treat adults with chronic hepatitis D ...

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease ...

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver ...

China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the ...